bluuebunny/crossref_metadata_2025_split huggingface dataset:
Impression management performances in a Brazilian mining company: The researcher as audience
Authors: Duarte Fernanda P 
Published: April 2011

AbstractWriting from an autoethnographic perspective, in this paper I re-visit Erving Goffman's ideas to examine impression management tactics used by staff from a large Brazilian mining company. The analysis is based on a 6-week fieldwork trip to Brazil in 2008 for the purpose of gathering qualitative data for a study on corporate social responsibility in the extractivist sector. Post-fieldwork reflections prompted the insight that during the data gathering phase of my research, I was subject to a series of impression management ‘performances’ by my corporate informants, carried out to foster a positive image of their company. In the paper I juxtapose data obtained during fieldwork and my personal reflections with selected excerpts from Goffman'sThe Presentation of Self in Everyday Life.
The distinctiveness of family-firm intangibles: A review and suggestions for future research
Authors: Huybrechts Jolien , Voordeckers Wim , Lybaert Nadine , Vandemaele Sigrid 
Published: April 2011

AbstractWe review the theoretical and empirical literature on the resource-based view in the context of family businesses using a framework of intangible resources. This approach allows us to structure the present research on value-adding resources in family firms into four clearly distinct groups – organizational culture, reputation, human capital and networks – and provides us with the opportunity to examine the interactions of these intangible resources. We use these relationships to offer a future research agenda that is focused on the creation of competitive advantage through the combination and recombination of these resources.
DNA Ligases
Authors: Lohman Gregory J.S. , Tabor Stanley , Nichols Nicole M. 
Published: April 2011

AbstractThe DNA ligase enzyme family catalyzes the formation of a phosphodiester bond between juxtaposed 5′‐phosphate and 3′‐hydroxyl termini in duplex DNA. This activity can seal nicks in duplex DNA or join double‐stranded DNA fragments having either blunt or cohesive ends. DNA ligases are central enzymes in molecular biology, nucleic acid research, and in next‐generation sequencing applications. Reaction conditions and applications for T4 DNA ligase, E. coli DNA ligase, and thermostable DNA ligases are described in this unit. These enzymes differ in their cofactor requirements, substrate specificity, and thermal stability. Curr. Protoc. Mol. Biol. 94:3.14.1‐3.14.7. © 2011 by John Wiley & Sons, Inc.
Gene and Genome Construction in Yeast
Authors: Gibson Daniel G. 
Published: April 2011

AbstractThe yeast Saccharomyces cerevisiae has the capacity to take up and assemble dozens of different overlapping DNA molecules in one transformation event. These DNA molecules can be single‐stranded oligonucleotides, to produce gene‐sized fragments, or double‐stranded DNA fragments, to produce molecules up to hundreds of kilobases in length, including complete bacterial genomes. This unit presents protocols for designing the DNA molecules to be assembled, transforming them into yeast, and confirming their assembly. Curr. Protoc. Mol. Biol. 94:3.22.1‐3.22.17. © 2011 by John Wiley & Sons, Inc.
LAMM syndrome with middle ear dysplasia associated with compound heterozygosity for FGF3 mutations
Authors: Sensi Alberto , Ceruti Stefano , Trevisi Patrizia , Gualandi Francesca , Busi Micol , Donati Ilaria , Neri Marcella , Ferlini Alessandra , Martini Alessandro 
Published: April 2011

AbstractWe report on the first cases ofFGF3compound heterozygotes in two European families from non‐consanguineous marriages, affected with labyrinthine aplasia, microtia, and microdontia (LAMM) Syndrome. Three not previously described mutations (p.W153VfsX51, p.Y106C, and p.Y49C) and a recurrent one (p.R104X) were found. Analysis of 50 unrelated control subjects (100 chromosomes) of the same European background did not show any of the two newly reported missense variations. We confirm the absence of otodental syndrome in heterozygous carriers, but report unilateral microtia in one of them. We also report on the involvement of the middle ear structures in LAMM Syndrome. © 2011 Wiley‐Liss, Inc.
HPPD: A newly recognized autosomal dominant disorder involving hypertelorism, preauricular sinus, punctal pits, and deafness mapping to chromosome 14q31
Authors: Sampath Srirangan , Keats Bronya J.B. , Lacassie Yves 
Published: April 2011

AbstractWe report on a novel autosomal dominant disorder with variable phenotypic expression in a three‐generation family; the major features include hypertelorism, preauricular sinus, deafness, and punctal pits with lacrimal‐duct obstruction. We ruled out the involvement of EYA1, SIX1, and SIX5 as candidate genes by direct sequencing of their exons and by SNP‐based linkage analysis. Subsequent SNP‐based whole‐genome genotyping and parametric multipoint linkage analysis gave lod scores >1 at 14q31 (LOD = 3.14), 11q25 (LOD = 1.87), and 8p23 (LOD = 1.18). By genotyping additional microsatellite markers at two of these three loci and using an expanded phenotype definition, the LOD at 14q31 increased to 3.34. Direct sequencing of the gene exons within the 14q31 critical interval and a custom aCGH experiment did not show any pathogenic mutation or copy‐number changes. Further sequencing of 21 kb of promoter regions showed a novel polymorphism 1,249 bp upstream from the SELIL start codon that segregated with the disease haplotype. Cloning the novel polymorphism into luciferase reporter constructs resulted in a 20% reduction in the expression levels. The identification of this family with a distinctive clinical phenotype and linkage to a novel locus at 14q31 supports the existence of a new syndrome of the branchial cleft. © 2011 Wiley‐Liss, Inc.
Replication study of genome‐wide associated SNPs with late‐onset Alzheimer's disease
Authors: Burns L.C. , Minster R.L. , Demirci F.Y. , Barmada M.M. , Ganguli M. , Lopez O.L. , DeKosky S.T. , Kamboh M.I. 
Published: April 2011

AbstractLate‐onset Alzheimer's disease (LOAD) is a multifactorial disease with the potential involvement of multiple genes. Four recent genome‐wide association studies (GWAS) have found variants showing significant association with LOAD on chromosomes 6, 10, 11, 12, 14, 18, 19, and on the X chromosome. We examined a total of 12 significant SNPs from these studies to determine if the results could be replicated in an independent large case–control sample. We genotyped these 12 SNPs as well the E2/E3/E4 APOE polymorphisms in up to 993 Caucasian Americans with LOAD and up to 976 age‐matched healthy Caucasian Americans. We found no statistically significant associations between the 12 SNPs and the risk of AD. Stratification by APOE*4 carrier status also failed to reveal statistically significant associations. Additional analyses were performed to examine potential associations between the 12 SNPs and age‐at‐onset (AAO) and disease duration among AD cases. Significant associations were observed between AAO and ZNF224/rs3746319 (P = 0.002) and KCNMA1/rs16934131 (P = 0.0066). KCNMA1/rs16934131 also demonstrated statistically significant association with disease duration (P = 0.0002). Although we have been unable to replicate the reported GWAS association with AD risk in our sample, we have identified two new associations with AAO and disease duration that need to be confirmed in additional studies. © 2011 Wiley‐Liss, Inc.
Greater effect of stroke thrombolysis in the presence of arterial obstruction
Authors: De Silva Deidre A. , Churilov Leonid , Olivot Jean‐Marc , Christensen Soren , Lansberg Maarten G. , Mlynash Michael , Campbell Bruce C.V. , Desmond Patricia , Straka Matus , Bammer Roland , Albers Gregory W. , Davis Stephen M. , Donnan Geoffrey A. ,   on behalf of the EPITHET‐DEFUSE Investigators
Published: April 2011

AbstractObjective:Recanalization of arterial obstruction is associated with improved clinical outcomes. There are no controlled data demonstrating whether arterial obstruction status predicts the treatment effect of intravenous (IV) tissue plasminogen activator (tPA). We aimed to determine if the presence of arterial obstruction improves the treatment effect of IV tPA over placebo in attenuating infarct growth.Methods:We analyzed 175 ischemic stroke patients treated in the 3–6 hour time window from the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) trial (randomized to IV tPA or placebo) and Diffusion and perfusion imaging Evaluation For Understanding Stroke Evolution (DEFUSE) study (all treated with IV tPA). Infarct growth was calculated as the difference between baseline diffusion‐weighted imaging (DWI) and final T2 lesion volumes. Baseline arterial obstruction of large intracranial arteries was graded on magnetic resonance angiography (MRA).Results:Among the 116 patients with adequate baseline MRA and final lesion assessment, 72 had arterial obstruction (48 tPA, 24 placebo) and 44 no arterial obstruction (33 tPA, 11 placebo). Infarct growth was lower in the tPA than placebo group (median difference 26ml, 95% confidence interval [CI], 1–50) in patients with arterial obstruction, but was similar in patients with no arterial obstruction (median difference 5ml, 95%CI, −3 to 9). Infarct growth attenuation with tPA over placebo treatment was greater among patients with arterial obstruction than those without arterial obstruction by a median of 32ml (95%CI, 21–43, p < 0.001).Interpretation:The treatment effect of IV tPA over placebo was greater with baseline arterial obstruction, supporting arterial obstruction status as a consideration in selecting patients more likely to benefit from IV thrombolysis. ANN NEUROL 2011;70:601–605
Gene therapy for pain: Results of a phase I clinical trial
Authors: Fink David J. , Wechuck James , Mata Marina , Glorioso Joseph C. , Goss James , Krisky David , Wolfe Darren 
Published: April 2011

AbstractObjective:Preclinical evidence indicates that gene transfer to the dorsal root ganglion using replication‐defective herpes simplex virus (HSV)‐based vectors can reduce pain‐related behavior in animal models of pain. This clinical trial was carried out to assess the safety and explore the potential efficacy of this approach in humans.Methods:We conducted a multicenter, dose‐escalation, phase I clinical trial of NP2, a replication‐defective HSV‐based vector expressing human preproenkephalin (PENK) in subjects with intractable focal pain caused by cancer. NP2 was injected intradermally into the dermatome(s) corresponding to the radicular distribution of pain. The primary outcome was safety. As secondary measures, efficacy of pain relief was assessed using a numeric rating scale (NRS), the Short Form McGill Pain Questionnaire (SF‐MPQ), and concurrent opiate usage.Results:Ten subjects with moderate to severe intractable pain despite treatment with >200mg/day of morphine (or equivalent) were enrolled into the study. Treatment was well tolerated with no study agent‐related serious adverse events observed at any point in the study. Subjects receiving the low dose of NP2 reported no substantive change in pain. Subjects in the middle‐ and high‐dose cohorts reported pain relief as assessed by NRS and SF‐MPQ.Interpretation:Treatment of intractable pain with NP2 was well tolerated. There were no placebo controls in this relatively small study, but the dose‐responsive analgesic effects suggest that NP2 may be effective in reducing pain and warrants further clinical investigation. ANN NEUROL 2011
Gadolinium‐conjugated folate–poly(ethylene glycol)–polyamidoamine dendrimer–carboxyl nanoparticles as potential tumor‐targeted, circulation‐prolonged macromolecular magnetic resonance imaging contrast agents. II
Authors: Zhang Wei‐Lu , Li Na , Huang Jin , Luo Shu‐Fang , Fan Ming‐Xia , Liu Shi‐Yuan , Muir Ben , Yu Jia‐Hui 
Published: April 2011

AbstractA new macromolecular gadolinium‐based magnetic resonance imaging (MRI) contrast agent, folic acid (FA)–poly(ethylene glycol) (PEG)–polyamidoamine dendrimer (PAMAM)–Gd, was synthesized with a core of PAMAM, which was modified with conjugates of FA and PEG and then chelated by gadolinium ions. The final products, with FA as the targeting moiety, were evaluated for their tumor‐targeting MRI contrast‐agent potential. The concentration detection limits in vitro; contrast‐enhanced MRI in the heart, kidney, and liver of mice; and metabolism of FA–PEG–PAMAM–Gd were measured by a Siemens Tim Trio human MRI scanner at 3 T. Transmission electron microscopy was used to determine the targeting of FA–PEG–PAMAM–Gd to human epidermoid carcinomas cell lines (KB) or murine aneuploid fibrosarcoma cell lines (L929). The toxicity was also assayed to evaluate the biocompatibility of this contrast agent. The minimum detectable concentration of FA–PEG4K–PAMAM–Gd (where the subscript 4K indicates a molecular weight of 4000 Da) was 15‐fold lower than that of the commercially available contrast agent gadopentetate dimeglumine. The MRI images displayed a gradual persistent signal enhancement on tumors, and millimeter‐sized (∼ 3 mm) tumors were well visualized with FA–PEG4K–PAMAM–Gd. In conclusion, the dendritic complexes were well suited for use as an FA‐mediated targeting contrast agent for early diagnosis of tumors in mice. The dendritic contrast agents displayed lower concentration detection limits, which suggests their future use in molecular imaging. © 2011 Wiley Periodicals, Inc. J Appl Polym Sci, 2011
Novel evidence‐based colchicine dose‐reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P‐glycoprotein inhibitors
Authors: Terkeltaub Robert A. , Furst Daniel E. , DiGiacinto Jennifer L. , Kook Karin A. , Davis Matthew W. 
Published: April 2011

AbstractObjectiveDrug–drug interactions can limit the safety of colchicine for treating rheumatic diseases. Seven separate drug–drug interaction (DDI) studies were performed to elucidate the in vivo effects of concomitant treatment with colchicine and known inhibitors of cytochrome P450 3A4 (CYP3A4)/P‐glycoprotein (cyclosporine, ketoconazole, ritonavir, clarithromycin, azithromycin, verapamil ER [extended release]), and diltiazem ER) on the pharmacokinetics of colchicine. The objective was to develop colchicine‐dosing algorithms with improved safety.MethodsAll studies were open‐label, non‐randomized, single‐center, one‐sequence, two‐period DDI experiments, using two 0.6‐mg doses of colchicine, separated by a minimum 14‐day washout period, followed by administration of the approved on‐label regimen of known CYP3A4/P‐glycoprotein inhibitors. Plasma concentrations of colchicine, but not the reference CYP3A4/P‐glycoprotein inhibitors, were determined, and the pharmacokinetic parameters were calculated.ResultsThe ratios of the maximum concentration and area under the curve from time 0 to infinity for colchicine plus CYP3A4/P‐glycoprotein inhibitors versus colchicine alone were >125% across all studies, with the exception of studies involving azithromycin. Significant DDIs were present when single doses of colchicine were coadministered with most of the selected CYP3A4/P‐glycoprotein inhibitors. Recommended colchicine dose reductions of 33–66% for the treatment of acute gout and 50–75% for prophylaxis were calculated for concomitant therapy with each agent, with the exception of no dose adjustment when colchicine is used in combination with azithromycin.ConclusionThese studies provide quantitative evidence regarding drug interactions and necessary adjustments in the dose of colchicine if colchicine treatment is continued during therapy with multiple CYP3A4/P‐glycoprotein inhibitors. We demonstrated the need for specific reductions in the dose of colchicine when it is used in combination with 2 broadly prescribed calcium channel blockers (verapamil ER and diltiazem ER) and that the dose of colchicine does not need to be adjusted when it is used in combination with azithromycin.
Nonlinear internal model based attitude tracking and disturbance rejection
Authors: Zhang Xuxi , Cheng Daizhan 
Published: April 2011

AbstractIn this paper, we consider the attitude tracking and disturbance rejection problem of rigid spacecraft, which is subject to some disturbances generated by nonlinear exosystems. A new nonlinear internal model is designed to manipulate the uncertainties caused by external disturbances, which includes the linear internal model as a special case. A numerical example is given to illustrate the theoretical result presented in the paper.Copyright © 2011 John Wiley and Sons Asia Pte Ltd and Chinese Automatic Control Society
American option prices in a Markov chain market model
Authors: van der Hoek John , Elliott Robert J. 
Published: April 2011

AbstractThis paper is a sequel to our previous paper ‘A New Paradigm in Asset Pricing’ in which we construct a model for asset pricing in a world where the randomness is modeled by a Markov chain. In this paper we develop a theory of optimal stopping and related variational inequalities for American options in this model. A version of Saigal's Lemma is established and numerical results obtained. Copyright © 2011 John Wiley & Sons, Ltd.
Funktionelle Akustik — Die Nachhall‐Charakteristik des Raumes als Basis für seine Nutzbarkeit
Authors: Fuchs Helmut V. 
Published: April 2011

AbstractIn Teil 1 dieser Serie wurde die aktuelle Ausgangssituation für eine funktionelle raumakustische Gestaltung skizziert. Die vorherrschenden Lehrmeinungen, Normen und Vorurteile, die unter Akustikern im Hinblick auf den anzustrebenden Nachhall von Räumen verschiedener Größe und Bestimmung gepflegt werden, wurden kritisch hinterfragt. Dabei wurde auf die häufigen Probleme bei tiefen Frequenzen, besonders in kleinen, aber auch in großen Räumen, hingewiesen. Hier wird nun mit weiteren Zitaten aus der Literatur an die vielfach unterschätzte Bedeutung des Bassbereichs erinnert. An einem unter Musikern und Tonschaffenden unisono gerühmten Kirchenraum mit herausragend guten raumakustischen Eigenschaften wird danach demonstriert, wie eindeutig positiv sich eine Absenkung des Nachhalls bei den Tiefen bei gleichzeitiger Anhebung bei den Höhen auf die Darbietung und Aufnahme von jeglicher Sprache und Musik auswirkt. Dazu kommen auch zahlreiche Nutzer mit ihren professionellen Wahrnehmungen gerade dieses Raumes zu Wort.Functional acoustics — useability of rooms based on reverberation characteristics. Part 2: Bass foundation and frequency spectrum of reverberation. In Part 1 of this series the present working conditions for a functional room‐acoustic design were outlined. The prevailing doctrines, standards and preoccupations were critically questioned which are cultivated by acousticians with respect to the desirable reverberation of rooms of differing size and use. Frequent problems were identified at the low frequencies especially in small, but also in large rooms. Here the often depreciated relevance of the bass regime will be underlined by further citations. A church room which is highly esteemed by musicians and sound engineers for its outstanding acoustical quality demonstrates the positive influence of a suppression of the reverberation at the low and simultaneous enhancement at the high frequencies on the performance and recording of speech and music. Numerous users of this room support these conclusions with their professional sensations.
Gebäudeenergieausweis in der Schweiz — Methodik des GEAK®
Authors: Hall Monika 
Published: April 2011

AbstractDer Gebäudeenergieausweise der Kantone GEAK® ist seit über einem Jahr in der Schweiz erfolgreich eingeführt. Anfang August 2009 wurde der GEAK® als Onlinetool aufgeschaltet und der Öffentlichkeit zugänglich gemacht. Der GEAK® ist ein kombinierter Gebäudeenergieausweis. Der Energiebedarf wird auf der Basis der Gebäudedaten rechnerisch ermittelt und dieser mit effektiven Verbrauchsdaten validiert. Kernstück des GEAK® ist eine Energieetikette mit Doppelbewertung: Eine Klassierung nach “Effizienz Gebäudehülle” für die Beurteilung der Gebäudehülle und nach ”Effizienz Gesamtenergie” zur Quantifizierung des gesamten Gebäudes inkl. Gebäudetechnik und Elektrizitätsbedarf für Geräte und Beleuchtung. Weiter enthält der GEAK® eine Beschreibung des Ist‐Zustandes der Gebäudehülle und ‐technik sowie Massnahmen und Empfehlungen energietechnischer Verbesserungen. Zukünftig können im Rahmen des GEAK® Plus Varianten von kostenoptimierten Sanierungsmaßnahmen detailliert zusammengestellt werden.Energy Performance Certificate in Switzerland — Methodology of GEAK®. More then one year the energy performance certificate of Switzerland GEAK® is well‐established. In the beginning of August 2009 the GEAK® started as a public online tool. The certificate is a combination of energy performance based on calculated values and consumption data. The calculated energy demand could be validated with consumption data. The core of the certificate is an energy rating with two classifications. The classification of the efficiency building envelope describes the thermal quality of the envelope and the classification of the overall energy performance of the building describes the energy efficiency of the whole building incl. building services, lighting and appliances. The certificate contains the energy rating, the description of the building in the current state and advices for efficient improvements. In the future, proposals of cost optimized reconstructions possibilities could be done with an additionally GEAK® Plus tool.
No effects of pulsed electromagnetic fields on expression of cell adhesion molecules (integrin, CD44) and matrix metalloproteinase‐2/9 in osteosarcoma cell lines
Authors: Zhang Daguang , Pan Xin , Ohno Shuichiro , Osuga Tomoaki , Sawada Shigeyuki , Sato Keiji 
Published: April 2011

AbstractPulsed electromagnetic fields (PEMF) could enhance the cytocidal effects of chemotherapeutic drugs on malignant tumor cell lines, but metastasis effects of PEMF on tumor cells have not been investigated. We investigated the effects of PEMF exposure on the expression levels of some metastasis‐related molecules, including integrin α subunits (α1, α2, α3, α4, α5, α6, αv), integrin β subunits (β1, β2, β3, β4), CD44, and matrix metalloproteinase‐2/9 (MMP‐2/9) in four human osteosarcoma cell lines (HOS, MG‐63, SAOS‐2, NY) and two mouse osteosarcoma cell lines (DOS, LM8) by using FACScan analysis, gelatin zymography, and Western blot analysis. Our results indicate that PEMF exposure has no effect on the expression of some molecules that are associated with tumor cell invasion and metastasis, and therefore suggest that PEMF exposure may be safely applied to chemotherapy for osteosarcoma. Bioelectromagnetics 32:463–473, 2011. © 2011 Wiley‐Liss, Inc.